First Pacific Advisors Has Trimmed Holding in Oracle (ORCL) by $1.39 Million; Hikari Power LTD Has Cut Its Bristol (BMY) Position by $439,200

May 22, 2018 - By Ellis Scott

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Robert Rodriguez decreased its stake in Oracle Corporation (ORCL) by 0.14% based on its latest 2017Q4 regulatory filing with the SEC. First Pacific Advisors Llc sold 29,534 shares as the company’s stock declined 4.18% with the market. The hedge fund run by Robert Rodriguez held 21.10 million shares of the prepackaged software company at the end of 2017Q4, valued at $997.77 million, down from 21.13 million at the end of the previous reported quarter. First Pacific Advisors Llc who had been investing in Oracle Corporation for a number of months, seems to be less bullish one the $189.99 billion market cap company. The stock decreased 1.42% or $0.67 during the last trading session, reaching $46.54. About 11.68 million shares traded. Oracle Corporation (NYSE:ORCL) has risen 1.20% since May 22, 2017 and is uptrending. It has underperformed by 10.35% the S&P500.

Hikari Power Ltd decreased its stake in Bristol (BMY) by 8.49% based on its latest 2017Q4 regulatory filing with the SEC. Hikari Power Ltd sold 7,200 shares as the company’s stock rose 2.38% while stock markets declined. The institutional investor held 77,600 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $4.76M, down from 84,800 at the end of the previous reported quarter. Hikari Power Ltd who had been investing in Bristol for a number of months, seems to be less bullish one the $86.13 billion market cap company. The stock increased 0.84% or $0.44 during the last trading session, reaching $52.68. About 1.84M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since May 22, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

First Pacific Advisors Llc, which manages about $28.26 billion and $13.37 billion US Long portfolio, upped its stake in Analog Devices Inc (NASDAQ:ADI) by 36,580 shares to 4.07M shares, valued at $362.23M in 2017Q4, according to the filing. It also increased its holding in Occidental Petroleum Corp (NYSE:OXY) by 10,980 shares in the quarter, for a total of 788,960 shares, and has risen its stake in Laboratory Corp Amer Hldgs (NYSE:LH).

More recent Oracle Corporation (NYSE:ORCL) news were published by: Seekingalpha.com which released: “Oracle To Acquire DataScience For Workflow Technologies” on May 22, 2018. Also Fool.com published the news titled: “Better Buy: International Business Machines (IBM) vs. Oracle (ORCL)” on May 09, 2018. Seekingalpha.com‘s news article titled: “Oracle buys DataScience.com” with publication date: May 16, 2018 was also an interesting one.

Among 43 analysts covering Oracle (NYSE:ORCL), 27 have Buy rating, 0 Sell and 16 Hold. Therefore 63% are positive. Oracle had 116 analyst reports since July 30, 2015 according to SRatingsIntel. Credit Suisse maintained Oracle Corporation (NYSE:ORCL) rating on Friday, September 15. Credit Suisse has “Buy” rating and $62.0 target. The firm has “Buy” rating by Cowen & Co given on Monday, September 11. The stock of Oracle Corporation (NYSE:ORCL) has “Outperform” rating given on Friday, September 16 by BMO Capital Markets. Credit Suisse maintained Oracle Corporation (NYSE:ORCL) rating on Thursday, October 12. Credit Suisse has “Buy” rating and $62.0 target. The rating was maintained by Stifel Nicolaus on Thursday, October 19 with “Buy”. Cowen & Co maintained the stock with “Buy” rating in Monday, October 23 report. The firm has “Buy” rating by Raymond James given on Friday, December 15. The firm earned “Mkt Perform” rating on Thursday, December 17 by FBR Capital. The firm has “Buy” rating given on Monday, July 24 by Stifel Nicolaus. As per Tuesday, March 20, the company rating was downgraded by Stifel Nicolaus.

Analysts await Oracle Corporation (NYSE:ORCL) to report earnings on June, 20. They expect $0.86 earnings per share, up 4.88% or $0.04 from last year’s $0.82 per share. ORCL’s profit will be $3.51B for 13.53 P/E if the $0.86 EPS becomes a reality. After $0.75 actual earnings per share reported by Oracle Corporation for the previous quarter, Wall Street now forecasts 14.67% EPS growth.

Investors sentiment increased to 1.15 in 2017 Q4. Its up 0.02, from 1.13 in 2017Q3. It improved, as 80 investors sold ORCL shares while 488 reduced holdings. 126 funds opened positions while 526 raised stakes. 2.29 billion shares or 1.37% less from 2.32 billion shares in 2017Q3 were reported. Court Place Advsr Ltd Liability Corporation reported 1.82% stake. Miles holds 5,300 shares. Wedgewood Invsts Pa holds 4,510 shares. 1.66 million were reported by Btim Corporation. Silvercrest Asset Management Group Inc Ltd Liability reported 288,299 shares or 0.13% of all its holdings. Wunderlich Cap Managemnt invested 0.9% of its portfolio in Oracle Corporation (NYSE:ORCL). Stack Financial Mgmt reported 4.11% in Oracle Corporation (NYSE:ORCL). Loring Wolcott Coolidge Fiduciary Llp Ma, a Massachusetts-based fund reported 4,876 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0.66% of its portfolio in Oracle Corporation (NYSE:ORCL). Rnc Mngmt Ltd owns 137,420 shares or 0.45% of their US portfolio. Gamble Jones Investment Counsel stated it has 0.11% in Oracle Corporation (NYSE:ORCL). Roanoke Asset Ny owns 71,303 shares for 1.61% of their portfolio. The New York-based Cipher Cap LP has invested 0.1% in Oracle Corporation (NYSE:ORCL). Colony Ltd Com invested in 0.88% or 296,536 shares. Gabelli Funds Ltd Liability Corp has invested 0% in Oracle Corporation (NYSE:ORCL).

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.09, from 1.03 in 2017Q3. It worsened, as 72 investors sold BMY shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported. Amer Interest Grp Incorporated Inc reported 0.11% stake. Argent Tru reported 52,404 shares. Mengis Cap owns 49,371 shares or 1.83% of their US portfolio. Fin Architects accumulated 0.14% or 13,590 shares. Burt Wealth Advsr accumulated 6,166 shares or 0.24% of the stock. Bsw Wealth holds 5,192 shares or 0.13% of its portfolio. Camarda Financial Advsrs Ltd has invested 1.59% in Bristol-Myers Squibb Company (NYSE:BMY). L S Advsr holds 0.05% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 5,635 shares. 10,700 were accumulated by Grantham Mayo Van Otterloo Ltd. Plante Moran Advisors Limited Com has 0.11% invested in Bristol-Myers Squibb Company (NYSE:BMY). Tiedemann Wealth Ltd Liability accumulated 0.03% or 5,665 shares. Keybank Natl Association Oh accumulated 808,122 shares. 5,820 were reported by Private Wealth Lc. Glg Limited has 0.74% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 169,273 shares. Polaris Greystone Financial owns 310,126 shares or 1.56% of their US portfolio.

Hikari Power Ltd, which manages about $846.83M US Long portfolio, upped its stake in Intuitive Surgical Inc (NASDAQ:ISRG) by 15,540 shares to 23,310 shares, valued at $8.51 million in 2017Q4, according to the filing. It also increased its holding in Allergan Plc by 19,100 shares in the quarter, for a total of 90,500 shares, and has risen its stake in Express Scripts Holding Inc (NASDAQ:ESRX).

Since December 12, 2017, it had 2 insider buys, and 1 sale for $163,963 activity. On Tuesday, December 12 Lynch Thomas J. Jr. sold $335,172 worth of Bristol-Myers Squibb Company (NYSE:BMY) or 5,300 shares. Paliwal Dinesh C bought $249,948 worth of Bristol-Myers Squibb Company (NYSE:BMY) on Monday, April 30.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Globenewswire.com which released: “Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations” on May 22, 2018, also Streetinsider.com with their article: “Morgan Finds Positive Datapoints For MRK and BMY At ASCO” published on May 17, 2018, Benzinga.com published: “BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position” on April 27, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Bizjournals.com and their article: “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer” published on May 01, 2018 as well as Fool.com‘s news article titled: “Why Bristol-Myers Squibb Stock Crashed in April” with publication date: May 09, 2018.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 2 Sell and 14 Hold. Therefore 27% are positive. Bristol-Myers Squibb Company had 87 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, April 26 by Robert W. Baird. The firm earned “Sell” rating on Sunday, July 23 by BMO Capital Markets. Barclays Capital maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Tuesday, December 1. Barclays Capital has “Equal Weight” rating and $70 target. Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE:BMY) on Thursday, February 15 to “Overweight” rating. Barclays Capital maintained the stock with “Equal-Weight” rating in Friday, September 9 report. The firm earned “Underperform” rating on Friday, July 28 by BMO Capital Markets. As per Friday, February 16, the company rating was maintained by Citigroup. The firm has “Buy” rating by Jefferies given on Monday, December 19. BMO Capital Markets maintained it with “Sell” rating and $49.0 target in Monday, November 13 report. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Hilliard Lyons on Tuesday, September 12.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on July, 26. They expect $0.86 earnings per share, up 16.22% or $0.12 from last year’s $0.74 per share. BMY’s profit will be $1.41 billion for 15.31 P/E if the $0.86 EPS becomes a reality. After $0.94 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -8.51% negative EPS growth.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>